293 results about "Metformin Hydrochloride" patented technology

Metformin Hydrochloride (herein referred to as metformin HCl) that may be 98.5%-100% pure is a high dose drug capable of being directly compressed with specific excipients into tablets having desired, hardness, disintegrating ability, and acceptable dissolution characteristics. Metformin HCl is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow metformin HCl to be compressed using the direct compression method. The tablets produced provide an acceptable in-vitro dissolution profile.

The invention relates to medical composition containing metformin and Vildagliptin and a preparation method thereof. The medical composition is formed by taking metformin chloride and Vildagliptin as medical active components and blending with pharmaceutically acceptable auxiliary materials; the invention adopts the metformin chloride and Vildagliptin as materials and adds auxiliary materials with some special kinds and proportions to prepare and develop diversified oral preparations such as tablets, capsules, granules, dispersible tablets, chewable tablets, buccal tablets, effervescent tablets, effervescent granules according to the technical method of the invention. The medical composition of the invention can be used for treating diabetes type II that can not be properly cured by alimentary control and sports and also for diabetes type II that can not be controlled by simply using metformin chloride or Vildagliptin.

The invention discloses a quality control method of metformin hydrochloride enteric coated tablet, comprising the aspects of character, identification, examination and content measurement; wherein, release examination comprises the release quantity examination of acid in hydrochloric acid solution of 0.1 mol/l and the release quantity examination in phosphate buffer with the pH value of 6.8; the examination of relevant substances comprises the following steps: dicyandiamide is taken as reference, sulfonic group cation exchange bonded silica is taken as filler, ammonium dihydrogen phosphate solution of 1.7 percent with the pH value of 3 is mobile phase and the high performance liquid chromatography is used for examining the relevant substances. The invention controls the release quantity of the metformin hydrochloride enteric coated tablet in gastric juice strictly, reduces the adverse reaction of patients effectively, improves the release quantity of the metformin hydrochloride enteric coated tablet in the buffer solution (simulated intestinal juice) and ensures the dissolution of the enteric coated tablet in the intestinal juice effectively; the invention also adds the examination of dicyandiamide impurity under the examination item and enhances the safety of the medicine.

The invention discloses fuscoporia obliqua active ingredients capable of lowering blood sugar and a preparation method and application of the fuscoporia obliqua active ingredients. The preparation method takes fuscoporia obliqua fruit body as raw material and comprises the following steps: respectively extracting, filtering and concentrating the fuscoporia obliqua fruit body with normal temperature water and high temperature water; adding alcohol into concentrate and depositing to obtain crude polysaccharide; respectively pouring the polysaccharide extracted with normal temperature water and the crude polysaccharide extracted with high temperature water to flow through a (diethylaminoethanol) DEAE-52 cellulose column; carrying out subsection elution by using distilled water and NaCl solutions with different concentrations; and collecting stepwise elution peak sugar solution. Internal blood sugar reduction activity experiment shows that 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with normal temperature water and 0.2mol/L NaCl-section eluted sugar of the crude polysaccharide extracted with high temperature water both have obvious blood sugar reduction activity, same blood sugar reduction activity with the blood sugar reduction medicine of metformin hydrochloride, and no obvious toxic or side effect.

The invention discloses a biguanide anti-diabetes medicine, in particular to a metformin hydrochloride enteric-coated medicine compound. The medicine compound is provided with a. a hollow pill core; b. a biguanide anti-diabetes medicine active component layer which is covered outside the hollow pill core; c. an enteric-coated layer which is covered outside the biguanide anti-diabetes medicine active component layer. The invention also discloses a method of preparing the medicine compound.

The invention discloses a metformin hydrochloride enteric-coated tablet, which comprises a tablet core and an enteric-coated layer. The tablet core is prepared by the following raw materials by weight: 100 parts of metformin hydrochloride, 3-5 parts of povidone K30, 8-12 parts of 75% ethanol water containing 10% povidone K30 and 0.5-1.0 part of magnesium stearate. The enteric-coated layer is prepared by the following raw materials by weight: 100 parts of eudragit L30D-55, 10-30 parts of talcum powder, 2-4 parts of polyethylene glycol 4000, 4-6 parts of 4% sodium hydroxide solution and 80-120 parts of purified water. The preparation process includes the steps of weighing all raw materials according to proportion, preparing the tablet core, preparing enteric-coated solution and then obtaining the metformin hydrochloride enteric-coated tablet. The metformin hydrochloride enteric-coated tablet simplifies preparation technology, effectively reducing manufacture cost, can simultaneously control releasing speed, and effectively guarantees clinical effects of products.

The invention provides a Metformin Hydrochloride slow release tablet and process for preparation, wherein the slow release tablet comprises metformin hydrochloride 46.5-70%, hydroxypropylcellulose 13.5-33.0%, micronization ethyl cellulose 10.0-14.0%, filling agent 1.3%-9.4%, and lubricating agent 1.2-1,5%. The preparation process comprises processing the prescribed raw material of metformin hydrochloride, cellulose glycollic ether, and the filling agent through the conventional tablet production process of granulation, drying, granulating, charging micronization ethyl cellulose, mixing homogenously with lubricant and tabletting.

The invention discloses an oral solid drug composition containing metformin hydrochloride repaglinide, which contains pharmaceutically acceptable carriers. The preparation process is simple, the problem of chipping is effectively solved, and simultaneously, the repaglinide has good content uniformity and dissolution; and the oral solid drug composition is used for treating type II diabetes.

The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.

The present invention relates to metformin glycinate salt and pharmaceutical compositions thereof for the treatment of diabetes mellitus. The method includes administration of the metformin glycinate salt by various routes selected from oral, intravenous injectable, intramuscular injectable, nasal, intraperitoneal, or sublingual, in order to achieve a reduction in blood glucose levels. The invention further relates to the synthesis of a new 1,1-dimethylbiguanide glycinate salt, called Metformin Glycinate. The resulting salt exhibits advantages over other metformin salts. These advantages are due, in the first place, to the fact that the glycine counterion exhibits hypoglycemic effects by itself. Moreover, the salt exhibits more rapid absorption, reaching higher plasma concentrations than those produced with metformin hydrochloride.

The invention discloses metformin hydrochloride sustained-release tablets which are characterized in that: every 10000 tablets are prepared from medicine materials and auxiliary materials of, by weight: 5000g of metformin hydrochloride, 1750g of hypromellose, 1750g of sodium carboxymethyl cellulose, 180g of stearic acid, 200g of magnesium stearate, and an appropriate amount of 75% ethanol. The metformin hydrochloride sustained-release tablets can be slowly released in vivo. With the tablets, stability of blood drug level can be maintained, and a half-life period is prolonged. The tablets are safe, can be used for treating type II diabetes, and are advantaged in high efficiency, low toxicity, and convenient administration. The invention also provides a preparation method of the metformin hydrochloride sustained-release tablets.

The invention discloses metformin hydrochloride sustained-release tablets and a preparation method thereof. The sustained-release tablets achieve a slow release effect by means of a slow release agent and a coating, wherein the slow release agent is a composition prepared from sodium carboxymethyl cellulose and pregelatinized starch; a coating solution is prepared by dissolving ethyl cellulose and other components in ethanol with mass fraction of 95%, wherein other components comprise polyethylene glycol 6000 and hexadecanol; hydroxypropyl methylcellulose is dissolved in purified water so as to be prepared into adhesive. The metformin hydrochloride sustained-release tablets can enable medicines to be slowly released in a human body and maintain an effective blood concentration, thus improving the compliance and safety of patients who take the medicines. The preparation method of the product is safe and reliable, and can realize large-scale production.

The invention discloses a preparation method of metformin hydrochloride. The method is characterized by including the following steps of firstly, adding dicyandiamide and dimethylamine hydrochloride in a reaction still, and adding cyclohexanol, wherein the mole ratio of dicyandiamide to dimethylamine hydrochloride is 1:1.2, and the mole ratio of cyclohexanol to dicyandiamide is 3:1; secondly, starting a stirring device, controlling the rotating speed at 45-50 r/min, regulating the vacuum degree in the reaction still to 0.08-0.09 MPa, heating the mixture to 135-145 DEG C, and preparing crude metformin hydrochloride after the reaction is conducted for 2.5 hours; thirdly, conducting recrystallization on the crude product through ethyl alcohol, and conducting filtering and drying to obtain the metformin hydrochloride. By means of the method, the reaction time is greatly shortened, the production cost is reduced, side reactions can be effectively restrained, the impurity content is reduced, and therefore the yield of the product is greatly improved.

The invention provides a compound preparation of pioglitazone hydrochloride and metformin hydrochloride bilayer osmotic pump controlled release tablets. The compound preparation structurally comprises the following parts from inside to outside in sequence: a tablet core comprising a drug layer and a digestive layer, an insulation coating layer, a controlled release coating film with drug release holes, a rapid pioglitazone hydrochloride release layer and an unnecessary attractive coating. The invention also provides a preparation method of the compound preparation of pioglitazone hydrochloride and metformin hydrochloride bilayer osmotic pump controlled release tablets. The preparation method comprises the following steps of: (1) preparing the drug layer; (2) preparing the digestive layer; (3) tabletting the tablet core; (4) coating insulation coating layer; (5) coating the controlled release coating; (6) punching the coated tablet: (7) coating the rapid pioglitazone hydrochloride release layer; and (8) coating the attractive coating.